Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05292911 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT05292911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
Altimmune, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 9, 2022
Completion date
October 31, 2022
Enrollment
64 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease